Focus: Cocrystal Pharma is a public biotech company focused on antiviral drug development targeting infectious diseases and neurology, headquartered in Bothell, WA. The company is early-stage with a pre-revenue model and a portfolio concentrated in Phase 1–2 clinical programs.
Profile data last refreshed 16h ago · AI intelligence enriched 1w ago
No open roles listed right now. Follow Cocrystal Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Cocrystal Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Cocrystal Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Cocrystal Pharma’s new CEO hopes to crack the norovirus code - Pharma Voice
Cocrystal Pharma’s new CEO hopes to crack the norovirus code Pharma Voice
Cocrystal Pharma’s new CEO hopes to crack the norovirus code - Yahoo Finance
Cocrystal Pharma’s new CEO hopes to crack the norovirus code Yahoo Finance
8-K Filing: Inmune Bio, Inc. (INMB) (CIK 0001711754) — CURRENT REPORT
CURRENT REPORT
This Beaten Down Biotech Stock Has A Secret Billionaire Backer Camaiore (r3LtPfZ5Ru) - Unisba Media
This Beaten Down Biotech Stock Has A Secret Billionaire Backer Camaiore (r3LtPfZ5Ru) Unisba Media
Cocrystal completes dosing in norovirus drug trial - Investing.com
Cocrystal completes dosing in norovirus drug trial Investing.com
Cocrystal Pharma Announces Last Subject Dosed in Phase 1b - GlobeNewswire
Cocrystal Pharma Announces Last Subject Dosed in Phase 1b GlobeNewswire
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Short-duration treatment with the novel non-nucleoside inhibitor CDI-31244 plus sofosbuvir/velpatasvir for chronic hepatitis C: An open-label study.
Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo